Start of Phase 1 ascending dose studies in recurrent or metastatic solid tumors with DT-9045 is expected by mid-2025 DT-9045 builds upon the Company’s growing pipeline which includes the ...

Domain Therapeutics SA has nominated PAR2 antagonist DT-9046 as a drug candidate with potential to treat various inflammatory diseases, including atopic dermatitis, inflammatory bowel disease and ...

A new "obesity drug" may block the effects of high sugar and fat diets. Scientists reports on how an abnormal amount of the inflammatory protein, PAR2, appears in abdominal fat tissue of overweight ...

DT-9046 is a highly differentiated first-in-class biased negative allosteric modulator of PAR2 with game changing potential across multiple inflammatory diseases Unique mechanism of action with ...